Notification of any allocation of convertible debentures not supported by unit rights is expected to be distributed around 16 December 2004. Trading with the convertible debentures is expected to commence on or about 29 December 2004.
Lund 15 December 2004
Active Biotech AB (publ)
Sven Andréasson
President & CEO
For further information, please contact:
Sven Andréasson, President and CEO, telephone: +46 46 19 20 49
Hans Kolam, CFO, telephone: +46 46 19 20 44
Cecilia Hofvander, Manager Corporate Communication, telephone: +46 46 19 11 22
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/ inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases, as well as a novel concept for use in cancer immunotherapy.
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
www.activebiotech.com